Trial Search Results

A Study of Pemetrexed in Children With Recurrent Cancer

To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company

Collaborator: Children's Oncology Group

Stanford Investigator(s):


  • Drug: pemetrexed


Phase 2


Inclusion Criteria:

   - Patients must have osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma,
   rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma

   - Measurable disease

   - Eastern Cooperative Oncology Group (ECOG) performance 0,1,2

   - Adequate renal, liver and bone marrow function

   - Patient's current disease state must be one with no known curative therapy or therapy
   proven to prolong survival with an acceptable quality of life

Exclusion Criteria:

   - Growth factors that support platelet or white cell number or function must not have
   been administered within the last 7 days prior to enrollment (14 days if Neulasta)

   - Patients with central nervous system (CNS) tumors who have not been on a stable or
   decreasing dose of dexamethasone or other corticosteroid for 7 days prior to

   - Patients with uncontrolled infection

   - Patients who have received pemetrexed previously

   - Patients with pleural effusions or ascites

Ages Eligible for Study

N/A - 22 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer Lew
Not Recruiting